One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

Alumis Inc. ALMS shares tumbled Monday despite strong clinical trial outcomes, as investors locked in gains following a 239% ...

Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch ...

Three men confront hair loss and find confidence in shaving it off — and experts explain why it feels empowering.

Understand how step therapy affects psoriasis treatment. Learn about the ‘fail first’ process, the impact of treatment delays ...

Once-daily oral zasocitinib for moderate to severe plaque psoriasis demonstrated rapid and durable skin clearance and a ...

Patients with moderate to severe CSU have greater rates of several immune-mediated comorbidities than patients with mild CSU.

In adults with psoriasis, IL-23 inhibitors were associated with lower risks for serious infection and all-cause mortality but higher malignancy risk.

Melinda Gooderham, MD, MSc, FRCPC, discusses findings from the Latitude PsO 3001 and Latitude PsO 3002 studies evaluating zasocitinib. This content was developed independently and is not endorsed by ...

Adults with moderate to severe hidradenitis suppurativa experienced substantial long-term symptom relief and quality of life ...